Neuropilin-2 expression promotes TGF-β1-Mediated epithelial to mesenchymal transition in colorectal cancer cells

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Grandclement, Camille ^a,b,c   Pallandre, Jean René ^a,b,c   Degano, Séverine Valmary ^d   Viel, Erika ^d   Bouard, Adeline ^a,b,c   Balland, Jérémy ^a,b,c   Rémy Martin, Jean Paul ^a,b,c   Simon, Benoit ^b   Rouleau, Alain ^b   Boireau, Wilfrid ^b   Klagsbrun, Michael ^e   Ferrand, Christophe ^a,b,c   Borg, Christophe ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; CYTOKERATIN 20; NEUROPILIN 2; SD 208; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL SHAPE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; CELL PROLIFERATION; CELL TRANSFORMATION; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEUROPILIN-2; PHOSPHORYLATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79959806137     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020444     Document Type: Article

References (49)

1. He Z, Tessier-Lavigne M, (1997) Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 90: 739-751.
2. Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, et al. (2002) Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A 99: 3657-3662.
3. Favier B, Alam A, Barron P, Bonnin J, Laboudie P, et al. (2006) Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 108: 1243-1250.
4. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M, (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 85: 357-368.
5. Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, et al. (2008) Blocking Neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13: 331-342.
6. Liu BP, Strittmatter SM, (2001) Semaphorin-mediated axonal guidance via Rho-related G proteins. Curr Opin Cell Biol 13: 619-626.
7. Cai HB, Reed RR, (1999) Cloning and characterization of neuropilin-1 interacting protein: A PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J Neurosci 19: 6519-6527.
8. Handa A, Tokunaga T, Tsuchida T, Lee YH, Kijima H, et al. (2000) Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. Int J Oncol 17: 291-295.
9. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, et al. (2000) Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115: 1000-1007.
10. Kawakami T, Tokunaga T, Hatanaka H, Kijima H, Yamazaki H, et al. (2002) Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 95: 2196-2201.
11. Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, et al. (2001) Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A 98: 13954-13959.
12. Rieger J, Wick W, Weller M, (2003) Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. Glia 42: 379-389.
13. Fakhari M, Pullirsch D, Abraham D, Paya K, Hofbauer R, et al. (2002) Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and-2 in human neuroblastoma. Cancer 94: 258-263.
14. Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, et al. (2008) Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 100: 109-120.
15. Dallas NA, Gray MJ, Xia L, Fan F, van Buren G 2nd, et al. (2008) Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin Cancer Res 14: 8052-8060.
16. Cohen T, Herzog Y, Brodzky A, Greenson JK, Eldar S, et al. (2002) Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours. J Pathol 198: 77-82.
17. Fukahi K, Fukasawa M, Neufeld G, Itakura J, Korc M, (2004) Aberrant expression of neuropilin-1 and-2 in human pancreatic cancer cells. Clin Cancer Res 10: 581-590.
18. Yasuoka H, Kodama R, Tsujimoto M, Yoshidome K, Akamatsu H, et al. (2009) Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. BMC Cancer 7: 220.
19. Vales A, Kondo R, Aichberger KJ, Mayerhofer M, Kainz B, et al. (2007) Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma 48: 1997-2007.
20. Cai Y, Wang R, Zhao YF, Jia J, Sun ZJ, et al. (2010) Expression of Neuropilin-2 in salivary adenoid cystic carcinoma: Its implication in tumor progression and angiogenesis. Pathol Res Pract.
21. Calicchio ML, Collins T, Kozakewich HP, (2009) Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Am J Pathol 174: 1638-1649.
22. Osada R, Horiuchi A, Kikuchi N, Ohira S, Ota M, et al. (2006) Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 37: 1414-1425.
23. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, et al. (2003) Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 163: 505-516.
24. Guarino M, (2007) Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 39: 2153-2160.
25. Boireau W, Rouleau A, Lucchi G, Ducoroy P, (2009) Revisited BIA-MS combination: entire "on-a-chip" processing leading to the proteins identification at low femtomole to sub-femtomole levels. Biosens Bioelectron 24: 1121-1127.
26. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, et al. (2010) Membrane Hsp72 from tumor-derived exosomes mediates pStat3 dependent immunosuppressive function of myeloid derived suppressor cells through the TLR2-MyD88 pathway. Journal of Clinical Investigation 120: 457-471.
27. Costa R, Carneiro A, Rocha A, Pirraco A, Falcão M, et al. (2009) Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study. J Cell Biochem 108: 1410-1417.
28. Futamura M KH, Miyamoto Y, Kitamura N, Nakamura Y, Ohnishi S, Masuda Y, Arakawa H, (2007) Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p21.3, in p53-regulated tumor angiogenesis suppression. Cancer Res 15: 1451-1460.
29. Mak P, Leav I, Pursell B, Bae D, Yang X, et al. (2010) ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 17: 319-332.
30. Lee JM, Dedhar S, Kalluri R, EW T, (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981.
31. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83.
32. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939.
33. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, et al. (2009) Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 1: 338-351.
34. Beiter K, Hiendlmeyer E, Brabletz T, Hlubek F, Haynl A, et al. (2005) beta-Catenin regulates the expression of tenascin-C in human colorectal tumors. Oncogene 24: 8200-8204.
35. Piek E, Moustakas A, Kurisaki A, Heldin CH, (1999) TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 112 4557-4568.
36. Portella G, Cumming SA, Liddell J, Cui W, Ireland H, et al. (1998) Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ 9: 393-404.
37. Glinka Y, Prud'homme GJ, (2008) Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J Leukoc Biol 84: 302-310.
38. Glinka Y, Stoilova S, Mohammed N, Prud'homme GJ, (2010) Neuropilin-1 exerts coreceptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis.
39. Cao Y, Szabolcs A, Dutta SK, Yaqoob U, Jagavelu K, et al. (2010) Neuropilin-1 mediates divergent R-Smad signaling and the myofibroblast phenotype. J Biol Chem.
40. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, et al. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65-74.
41. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, et al. (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62: 58-64.
42. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, et al. (2004) SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64: 7954-7961.
43. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, et al. (2005) Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 179: 56-65.
44. Geretti E, Shimizu A, Klagsbrun M, (2008) Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis 11: 31-39.
45. Ellis LM, (2006) The role of neuropilins in cancer. Mol Cancer Ther 5: 1099-1107.
46. Hendrix MJ, Seftor EA, Seftor RE, Trevor KT, (1997) Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 150: 483-495.
47. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, et al. (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 98: 10356-10361.
48. Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, et al. (2009) The epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology.
49. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A, (2005) TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 16.